程序性死亡受体1抗体联合白蛋白结合型紫杉醇治疗一线化疗后进展的晚期非小细胞肺癌的效果分析  

Analysis of the Effect of Programmed Death Receptor 1 Antibody Combined with Albumin-Bound Paclitaxel in the Treatment of Advanced Non-small Cell Lung Cancer After First-line Chemotherapy

作　　者：曹梦函 陈昊 韩正祥 杜秀平 CAO Meng-han;CHEN Hao;HAN Zheng-xiang;DU Xiu-ping(Department of Oncology,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu Province,221000 China;Department of Respiratory Medicine,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu Province,221000 China)

机构地区：[1]徐州医科大学附属医院肿瘤内科,江苏徐州221000 [2]徐州医科大学附属医院呼吸内科,江苏徐州221000

出　　处：《中外医疗》2020年第36期4-6,10,共4页China & Foreign Medical Treatment

摘　　要：目的探讨程序性死亡受体1抗体联合白蛋白结合型紫杉醇治疗一线化疗后进展的晚期非小细胞肺癌的临床疗效。方法方便选择2018年1月—2019年12月该院收治的54例一线化疗后进展的晚期非小细胞肺癌患者为研究对象,依据治疗方法不同分为两组。对照组27例,患者行白蛋白结合型紫杉醇单药化疗;实验组27例,患者在对照组基础上加用程序性死亡受体1抗体联合化疗。比较观察两组疗效及不良反应。结果经治疗,实验组肿瘤客观缓解率44.44%,疾病控制率74.07%,均高于对照组,差异有统计学意义(χ^(2)=4.207、7.500,P<0.05)。Ⅲ~Ⅴ级严重不良反应发生率(22.22%)与对照组比较差异无统计学意义(χ^(2)=0.491,P>0.05)。结论一线化疗后进展的晚期非小细胞肺癌患者以程序性死亡受体1抗体联合白蛋白结合型紫杉醇治疗效果优于白蛋白结合型紫杉醇单药化疗,有助于提高肿瘤客观缓解率与疾病控制率,而且不明显增加或加重不良反应。Objective To investigate the clinical efficacy of programmed death receptor 1 antibody combined with albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer after first-line chemotherapy.Methods From January 2018 to December 2019,54 patients with advanced non-small cell lung cancer who had progressed after first-line chemotherapy were convenient selected as the research objects.They were divided into two groups according to different treatment methods.In the control group,27 patients received albumin-bound paclitaxel single-agent chemotherapy;in the experimental group,27 patients received programmed death receptor 1 antibody combined with chemotherapy on the basis of the control group.Compared and observed the efficacy and adverse reactions of the two groups.Results After treatment,the objective tumor response rate of the experimental group was 44.44%,and the disease control rate was 74.07%,which were higher than those of the control group.The difference was statistically significant(χ^(2)=4.207,7.500,P<0.05).Grade III-V severe incidence of adverse reactions(22.22%)was not statistically different from the control group,the difference was not statistically significant(χ^(2)=0.491,P>0.05).Conclusion In advanced non-small cell lung cancer patients with first-line chemotherapy,the therapeutic effect of programmed death receptor 1 antibody combined with albumin-bound paclitaxel is better than albumin-bound paclitaxel single-agent chemotherapy,which helps to improve the objective tumor remission rate and disease control rate,and does not significantly increase or aggravate adverse reactions.

关 键 词：晚期非小细胞肺癌 程序性死亡受体1抗体 白蛋白结合型紫杉醇 疗效 安全性 

分 类 号：R5[医药卫生—内科学]